The study evaluated long-term efficacy, safety, survival outcomes, and outcomes following subsequent therapy in patients with treatment-naïve chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) and del(17p) receiving zanubrutinib in SEQUOIA arm C.
This was a prospective, nonrandomized cohort study of patients with treatment-naïve CLL/SLL and centrally confirmed del(17p) who were aged ≥65 years and/or unsuitable for fludarabine, cyclophosphamide, and rituximab–based chemoimmunotherapy. Patients received zanubrutinib 160 mg twice a day until progressive disease (PD) or unacceptable toxicity. Endpoints included progression-free survival (PFS), time to next treatment (TTNT), time to next treatment or death (TTNT-D), time to second progression event or death (PFS2), overall survival (OS), safety, and outcomes following subsequent therapies. Adverse events (AEs) were monitored until PD or initiation of next-line therapy. PFS, PFS2, and OS analyses were also adjusted for COVID-19-related mortality.
The study enrolled 111 patients, of whom 110 had confirmed del(17p). At baseline, TP53 mutation, unmutated immunoglobulin heavy-chain variable region (IGHV), and complex karyotype (≥3 chromosomal abnormalities) were observed in 42.3%, 60.4%, and 27.9% of patients, respectively, with a median age of 71 years (range, 42-87). After a median follow-up of 87.6 months (range, 5.0-98.4 months), 49 patients (44.1%) remained on zanubrutinib. Among those who discontinued, the most common reasons were AEs (26.1%) and PD (20.7%).
At 78 months, the estimated PFS rate was 59.3% (95% CI, 48.9-68.3), or 60.0% (95% CI, 49.5-69.0) after adjustment for COVID-19. Consistent efficacy was observed regardless of IGHV status (estimated 78-month PFS rates: unmutated IGHV, 58.3% [95% CI, 44.5-69.8]; mutated IGHV, 62.6% [95% CI, 44.3-76.4]). Estimated TTNT and TTNT-D rates at 78 months were 78.0% (95% CI, 68.4-84.9) and 67.2% (95% CI, 57.3-75.2), respectively. Estimated 78-month PFS2 and OS rates were 78.4% (95% CI, 69.2-85.1) and 78.3% (95% CI, 69.2-85.0), respectively, with COVID-19-adjusted estimates of 80.1% (95% CI, 71.0-86.5) and 80.0% (95% CI, 71.0-86.5), respectively.
Among 27 patients (24.5%) who received subsequent anti-CLL therapy, 25 did so following PD. Of these, 18 patients received a B-cell lymphoma 2 (BCL-2) inhibitor-based regimen, five received chemoimmunotherapy, and two received a covalent/non-covalent Bruton tyrosine kinase inhibitor. After a median follow-up of 26 months from initiation of BCL-2 inhibitor-based therapy, 11 of 18 patients remained alive and progression-free, with an estimated 2-year PFS rate of 58.7% (95% CI, 28.3-79.8).
A total of 30 patients (27.0%) died, most commonly due to PD (n=11 [9.9%]) and AEs (n=9 [8.1%]), including two deaths (1.8%) that were considered treatment related. Grade ≥3 AEs of special interest (% of patients; exposure-adjusted incidence rate per 100 person-months) included infections (34.2%; 0.64), hypertension (10.8%; 0.18), second primary malignancies excluding non-melanoma skin cancers (9.9%; 0.16), hemorrhage (8.1%; 0.13), and atrial fibrillation/flutter (5.4%; 0.08).